(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 July 2009 (02.07.2009)

PCT

(10) International Publication Number
WO 2009/080701 A1

(51) International Patent Classification:
A23L 1/015 (2006.01) *A23K 1/18* (2006.01)
A23K 1/165 (2006.01) *C12N 9/18* (2006.01)

(21) International Application Number:
PCT/EP2008/067885

(22) International Filing Date:
18 December 2008 (18.12.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07150205.8 20 December 2007 (20.12.2007) EP

(71) Applicant: **NOVOZYMES A/S** [DK/DK]; Krogshoejvej 36, DK-2880 Bagsvaerd (DK).

(72) Inventors: **VIKSOE-NIELSEN, Anders**; Lindevej 12, Joerlunde, DK-3550 Slangerup (DK). **SOERENSEN, Birthe, Hauerbach**; Nyelandsvej 41 st. tv., DK-2000 Frederiksberg (DK).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(54) Title: CUTINASE FOR DETOXIFICATION OF FEED PRODUCTS

(57) Abstract: The present invention relates to a method comprising treatment with cutinase for detoxification of feed products contaminated by the mycotoxin zearalenone.

WO 2009/080701 A1

CUTINASE FOR DETOXIFICATION OF FEED PRODUCTS

REFERENCE TO A SEQUENCE LISTING

This application contains a Sequence Listing in computer readable form. The computer readable form is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to a method comprising treatment with cutinase for detoxification of feed products contaminated by the mycotoxin zearalenone.

BACKGROUND OF THE INVENTION

Several plant pathogenic and/or post-harvest *Fusarium* species on cereals produce toxic substances of considerable concern to livestock and poultry producers, e.g., deoxynivalenol, T-2 toxin, HT-2 toxin, diacetoxyscirpenol and zearalenone.

Zearalenone is found worldwide in a number of cereal crops, such as maize, barley, oats, wheat, rye, rice, millet and sorghum. Zearalenone production does not seem to occur in significant amounts prior to harvest, but under proper environmental conditions, it is readily produced on corn and small grains in storage.

When cereal grain is used in ethanol production and the starch is consumed the zearalenone is concentrated in the fermentation by-products, e.g., in the distiller's dried grain. The contents of zearalenone in the fermentation by-products may be increased three-fold relative to the cereal grain.

The toxin is heat-stable, and it is not destroyed by long storage, roasting, or by the addition of propionic acid or mold retardants.

Despite their structural dissimilarity to the steriodal estrogens, zearalenone and several of its derivatives possess estrogenic activity. Zearalenone undergoes a folding such that hydroxyl or potential hydroxyl groups become appropriately orientated to facilitate binding to tissue receptors that normally bind estrogens.

Zearalenone is the primary toxin causing infertility, abortion or other breeding problems, especially in swine. The symptoms are especially severe in prepubertal gilts including enlarged mammae, swelling of uterus and vulva, and atrophy of the ovaries. In severe cases, prolapse of the vulva and rectum may occur. Boars exhibit enlarged mammae and atrophied testes.

Zearalenone is present in the meat from animals feeding on contaminated grain as well as in bread baked from contaminated wheat. While cases of poisoning of humans are rare there is concern about the effect of the long term exposure of humans to such an estrogenic activity.

Inactivation of mycotoxins, including zearalenone, using epoxidase or lactonase is

disclosed in WO9612414.

There is a need for further methods of detoxification of animal feed products, e.g., such as fermentation by-products, including distiller's wet and dried grain, contaminated by the mycotoxin zearalenone.

SUMMARY OF THE INVENTION

The inventors of the present invention have discovered that zearalenone in a feed product can be degraded by treating the feed product with a cutinase. Accordingly, in a first aspect the invention provides a process for degrading zearalenone in a feed product which process comprises treating said feed product with a cutinase.

In a second aspect the invention provides a use of a cutinase for degrading a mycotoxin.

Detailed description of the invention

Zearalenone

In the context of this invention the term "zearalenone" comprises the mycotoxin zearalenone produced from certain *Fusarium* sp. The IUPAC name is (*4S,12E*)-15, 17-Dihydroxy-4-methyl-3-oxabicyclo[12.4.0]octadeca-12, 15, 17, 19-tetraene-2, 8-dione. The term "zearalenone" also comprises any derivative of zearalenone which comprises an internal carboxylic ester bond susceptible for modification by a cutinase.

Animal feed products

The term "animal" includes all animals, including human beings. Examples of animals are cattle, (including but not limited to cows and calves); mono-gastric animals, e.g. pigs or swine (including, but not limited to, piglets, growing pigs, and sows); poultry such as turkeys and chicken (including but not limited to broiler chicks, layers); and fish (including but not limited to salmon).

The term "feed" or "feed product" means any compound, preparation, mixture, or composition suitable for, or intended for intake by an animal.

The feed product may be a product which apart from an unwanted level of zearalenone is suitable for consumption by an animal. The feed product can also be a product suspected of comprising an unwanted level of zearalenone, and/or a product having an unknown level of zearalenone, including products not comprising a detectable level of zearalenone.

Preferably the feed product is a grain based product. Preferably the grain based product comprises cereal(s), e.g., one or more of corn, wheat, barley, rye, rice, sorghum and millet. Also preferred are grain based product comprising material derived from one or more of corn, wheat, barley, rye, rice, sorghum and millet. In one embodiment, the feed product

may e.g. be derived solely from cereal(s), and in another embodiment partly from legumes, e.g. from soybean, and partly from cereals. The grain based product may comprise whole or milled grain, e.g., wet or dry milled grain, including grain based product comprising fractions of wet or dry milled grain, e.g., gluten, protein, starch, and/or oil fractions. Also preferred are products comprising a by-product from brewing and/or fermentation processes, e.g., spent grain. Spent grain is the by-products from the production of alcoholic beverages and ethanol fuels. Brewers' spent grain (BSG) is the residue of beer making in breweries, which use malted barley as the major raw material. Distiller's spent grain (DSG) is the product left in distilleries after alcohol is removed by distillation from the fermented grains such as corn, wheat, barley, rice, and rye. Distiller's spent grain is also known as distiller's grain. Wet distiller's grain (WDG) is dried to produce dried distiller's grain (DDG) which is used primarily as animal feed.

Cutinases

In the context of this invention the term "cutinases" include enzymes comprised by the enzyme classification E.C.3.1.1.74. Preferred are the below mentioned enzymes as well as enzymes with homologous sequence, especially recombinant and/or substantially purified enzymes.

The cutinase may be derived from a fungus. Particularly, the cutinase may be derived from a strain of *Humicola*, particularly *H. insolens*, more particularly *H. insolens* strain DSM1800 (US 5,827,719) or from a strain of *Fusarium*, e.g. *F. roseum culmorum*, or particularly *F. solani pisi* (WO 90/09446; WO 94/14964, WO 94/03578). The fungal cutinase may also be derived from a strain of *Rhizoctonia*, e.g. *R. solani*, or a strain of *Alternaria*, e.g. *A. brassicicola* (WO 94/03578). The cutinase may also be a variant of a parent cutinase such as those described in WO 00/34450, or WO 01/92502, all of which are hereby incorporated by reference. The cutinase may be the variant of the *Humicola insolens* cutinase comprising the substitutions E6Q, G8D, A14P, N15D, E47K, S48E, R51P, A88H, A91H, A130V, E179Q and R189V, which is disclosed at p. 24, line 11 of 10038.204-WO.

SEQ ID NO:1 is the amino acid sequence of the *Humicola insolens* cutinase (corresponding to the mature part of SEQ ID NO:2 of US 5,827,719, and of SEQ ID NO:1 of WO 01/92502), and SEQ ID NO:2 is the amino acid sequence of the *Fusarium solani pisi* according to Fig. 1D of WO 94/14964.

The cutinase must be present in the medium to be detoxified in effective amounts. Preferably the cutinase is present in concentrations of 0.01-100 mg enzyme protein pr. kg dry matter, preferably 0.1-10 mg enzyme protein pr. kg dry matter, or more preferably 1-5 mg enzyme protein pr. kg dry matter.

The medium

In an embodiment the cutinase is degrading the zearalenone in a medium comprising the feed product. The medium is preferably aqueous and may be a liquid, a paste or a slurry. To form a suitable medium water may be added to the feed product. The cutinase be comprised in solid or liquid formulations suitable for application to said medium.

In a embodiment the cutinase is degrading the zearalenone to an extent whereby the content of zearalenone per kg dry matter feed product is reduced to less than 50%, preferably less than 60%, more preferably less than 70%, and most preferably to less than 80% of the initial amount.

The detoxifixation efficiency of the invention depends on e.g. availability of water, pH, temperature and buffer of the medium. For example, the treatment may take place at a pH-value at which the relative activity of the actual cutinase is at least 50, or 60, or 70, or 80 or 90%. Likewise, for example, the treatment may take place at a temperature at which the relative activity of the actual cutinase is at least 50, or 60, or 70, or 80 or 90%. The relative activity is calculated relative to the activity at the pH value where the highest activity is observed.

pH in the medium

Depending, inter alia, on the characteristics of the cutinase employed, the pH in the medium employed should normally be in the range of 5-11, preferably in the range 6-10, e.g. 6.5-8.5.

Temperature in the medium

Preferably a reaction temperature is applied which is close to the optimum temperature for the cutinase. In numerous embodiments of the invention, temperatures in the range of 10-65°C, more preferably 30-50°C, should be employed.

Treatment duration

The duration of treatment depends, inter alia, on the treatment type, the type of item to be treated, the properties of the medium, e.g. temperature and pH and the type and amounts of enzyme employed.

The enzymatic reaction is continued until the desired result is achieved, following which it may or may not be stopped by inactivating the enzyme, e.g., by a heat-treatment step.

For detoxification purposes treatment times in the range of 1 minute to 1 week may be employed. In many cases a treatment time in the range of 6 to 48 hours will be suitable.

Identity

The relatedness between two amino acid sequences or between two nucleotide

sequences is described by the parameter "identity".

For purposes of the present invention, the degree of identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, *J. Mol. Biol.* 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice *et al.*, 2000, *Trends in Genetics* 16: 276-277), preferably version 3.0.0 or later. The optional parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The output of Needle labeled "longest identity" (obtained using the –nobrief option) is used as the percent identity and is calculated as follows:

(Identical Residues x 100)/(Length of Alignment – Total Number of Gaps in Alignment)

For purposes of the present invention, the degree of identity between two deoxyribonucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, *supra*) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice *et al.*, 2000, *supra*), preferably version 3.0.0 or later. The optional parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output of Needle labeled "longest identity" (obtained using the –nobrief option) is used as the percent identity and is calculated as follows:

(Identical Deoxyribonucleotides x 100)/(Length of Alignment – Total Number of Gaps in Alignment)

Homologous sequence

The term "homologous sequence" is defined as a predicted protein that gives an E value (or expectancy score) of less than 0.001 in a tfasty search (Pearson, W.R., 1999, in *Bioinformatics Methods and Protocols*, S. Misener and S. A. Krawetz, ed., pp. 185-219) with a specified sequence.

The term "homologous sequence" may also be defined as a sequence that has a degree of identity at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or even 100%, to a specified sequence.

EXAMPLES

Example 1

Enzyme: A recombinantly produced enzyme composition comprising the variant of the cutinase from *Humicola insolance* disclosed at p. 24, line 11 of 10038.204-WO.

Assay: Reactions were performed in 300 microL volumes in eppendorf tubes comprising

zearalenone 30 microM, Tris 100 mM and enzyme 0.1 mg EP/mL. In control reactions the enzyme volume was substituted an equivalent amount of H_2O. The reactions were incubate 24 hours at 37°C before being terminated by adding 600 microL of a 100 microM acetonitrile stop solution. Reactions were stored at -20° C until chromatographic analysis.

Chromatographic analysis: Samples were centrifugated and the supernatant analysed for zearalenone by HPLC-DAD as described by Smedsgaard (*J. Chromatogr. A,* 1997, *760,* 264-270). The DAD scanned from 200-600 nm. Separation was done on a Phenomenex (Torrance, CA) Luna C18(2) 10×2 mm ID, 3 micrometer, column 2, using a linear gradient moving form 5% to 100% acetonitrile in 20 min. Residual zearalenone was calculated relative to the control. The results are presented in tables 1.

Table 1. Residual zearalenone after 24 hours incubation with or without a cutinase at pH 7.

Enzyme	**Residual zearalenone (%)**
Control	100
Cutinase	19

Claims

1. A process for degrading zearalenone in a feed product which process comprises treating said feed product with a cutinase.

2. The process according to claim 1 wherein the dosage of the cutinase is 0.01-100 mg enzyme protein pr. kg dry matter, preferably 0.1-10 mg enzyme protein pr. kg dry matter, or more preferably 1-5 mg enzyme protein pr. kg dry matter.

3. The process according to any of claims 1 or 2 wherein the feed product is a grain based feed product.

4. The process according to any of claims 1 to 3 wherein the feed product comprise one or more selected from corn, wheat, barley, rye, rice, sorghum and millet.

5. The process according to any of claims 1 to 4 wherein the feed product is an animal feed composition.

6. The process according to any of claims 1 to 5 wherein the feed product is a by-product from a fermentation process.

7. The process according to any of claims 1 to 6 wherein the feed product comprises brewer's spent grain, distiller's spent grain, distiller's wet grain, and/or distiller's dried grain.

8. The process according to any of claims 1 to 7 wherein the feed product is a swine feed product.

9. The process according to any of claims 1 to 8 wherein the cutinase is a cutinase having the sequence shown in SEQ ID NO:1 or a homologous sequence.

10. The process according to any of claims 1 to 9 wherein the cutinase is a variant of the cutinase shown in SEQ ID NO:1 comprising one or more, including all of the substitutions G8D, N15D, S48E, A88H, N91H, A130V and R189V.

11. The process according to any of claims 1 to 10 wherein the cutinase is a cutinase having the sequence shown in SEQ ID NO:2 or a homologous sequence.

12. A use of a cutinase for degrading a mycotoxin.

13. The use according to claim 12 wherein the mycotoxin is zearalenone.

14. The use according to any of claims 12 or 13 in a grain based feed product.

15. The use according to any of claims 12 to 14, wherein the dosage of the cutinase is 0.01-100 mg enzyme protein pr. kg dry matter, preferably 0.1-10 mg enzyme protein pr. kg dry matter, or more preferably 1-5 mg enzyme protein pr. kg dry matter.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2008/067885

A. CLASSIFICATION OF SUBJECT MATTER
INV. A23L1/015 A23K1/165 A23K1/18 C12N9/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A23L A23K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, FSTA, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2003/073239 A1 (KARLOVSKY PETR [DE] ET AL KARLOVSKY PETR [DE] ET AL) 17 April 2003 (2003-04-17) page 1, paragraphs 5,6,9 page 2, paragraphs 11,13,17	1-15
A	WO 2007/133263 A (GENENCOR INT [US]; CERVIN MARGUERITE A [US]; WHITED GREGG [US]) 22 November 2007 (2007-11-22) page 1, paragraph 2 page 3, paragraphs 8,9 page 23, paragraphs 83,85 page 24, paragraph 88	1-15

-/--

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
19 March 2009	24/04/2009

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Stiegler, Petra

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2008/067885

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96/12414 A (ERBER ERICH KG [AT]) 2 May 1996 (1996-05-02) cited in the application page 3, paragraphs 2,4 page 4, lines 15-28 page 5, lines 9-30 page 2, paragraph 2 page 3, paragraph 8 page 4, paragraph 10	1-15
A	EP 0 981 953 A (PIONEER HI BRED INT [US]) 1 March 2000 (2000-03-01) page 2, paragraph 2 page 3, paragraph 8 page 4, paragraph 10	1-15
A	MARION BRODHAGEN, NANCY P. KELLER: "Signalling pathways connecting mycotoxin production and sporulation" MOLECULAR PLANT PATHOLOGY, vol. 7, no. 4, 2006, pages 285-301, XP002478569 page 291, lines 12-22	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2008/067885

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2003073239 A1	17-04-2003	NONE	
WO 2007133263 A	22-11-2007	AU 2006343548 A1	22-11-2007
		CA 2633849 A1	22-11-2007
		EP 1954814 A2	13-08-2008
WO 9612414 A	02-05-1996	AT 504 U1	27-12-1995
		AT 175073 T	15-01-1999
		AU 3736595 A	15-05-1996
		BR 9509399 A	04-11-1997
		CA 2192983 A1	02-05-1996
		CN 1158554 A	03-09-1997
		CZ 9603683 A3	11-06-1997
		DE 59504703 D1	11-02-1999
		EP 0786945 A1	06-08-1997
		ES 2128086 T3	01-05-1999
		HR 950526 A2	30-04-1997
		HU 76374 A2	28-08-1997
		IL 115650 A	14-07-1999
		JP 2983639 B2	29-11-1999
		JP 9511657 T	25-11-1997
		PL 319755 A1	18-08-1997
		SK 167896 A3	04-06-1997
		ZA 9508786 A	13-05-1996
EP 0981953 A	01-03-2000	NONE	